Original ArticleSimvastatin Inhibits Tumor Growth and Migration by Mediating Caspase-1–Dependent Pyroptosis in Glioblastoma Multiforme
Introduction
Glioblastoma multiforme (GBM) is the most common cerebral malignancy in adults and has the highest mortality and morbidity among all central nervous system cancers. Despite great advances in surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapy, patients' prognosis is far from satisfactory. Even comprehensive treatment cannot significantly reduce the risk of recurrence, progression, or death from GBM. Therefore, there is an urgent need to better understand the biological behavior of GBM and explore other potential adjuvant therapies. Statins, synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are widely used in the clinical treatment of high blood cholesterol. Beyond their cholesterol-lowering properties, results from previous in vivo and in vitro studies verify statin-dependent anti-inflammatory effects,1,2 and such responses are associated with the remodeling process during atheromatic plaque stabilization.3 However, this inhibitory effect is independent of the cholesterol-reducing properties of statins.4 In addition to these properties, numerous experimental and clinical studies have unexpectedly demonstrated the antitumor effect of statins by inducing suppression of malignant cells5 or inducing apoptosis.4,6 Statins have been investigated for their beneficial effects on various types of cancer, including the carcinoma of the colon and rectum, liver, breast, skin, prostate, and lung.7, 8, 9, 10
Pyroptosis is a type of programmed cell death and is thought of as a regulated form of necrosis.11 Unlike apoptosis, pyroptosis is initiated by the binding of NOD-like receptors (NLRs) to pathogen-associated molecular patterns and danger-associated molecular patterns,12,13 which generate active caspase-1, leading to pore formation in the membrane and enzymolysis of the precursors for inflammatory cytokines IL-1β and IL-18. Pyroptosis results in cell swelling, cell lysis, release of cytosolic contents such as lactate dehydrogenase, and induction of the inflammatory cytokines IL-1β and IL-18.14, 15, 16 Accumulating evidence suggests that pyroptosis is involved in a variety of diseases, such as diabetic cardiomyopathy,17 alcoholic gastritis,18 hepatocellular carcinoma, gastric cancer,14 non–small-cell lung cancer,10 and oral squamous cell carcinoma.19 Moreover, earlier findings by our group confirmed that pyroptosis is involved in proliferation and migration in GBM cells.20 Considering the potential connection between statin, pyroptosis, inflammation, and tumors, we hypothesize that statins may exert antitumor efficiency by mediating pyroptosis in GBM.
Our previous work has demonstrated that pyroptosis is activated in GBM20 and miR-214-3p directly targets caspase-1, through which miR-214-3p inhibits cellular proliferation and migration in glioma cells. In the present study, we observed that simvastatin suppresses the proliferation, migration, and invasion of GBM cell lines by regulating caspase-1–dependent pyroptosis. Additionally, si-miR-214-3p reversed simvastatin's inhibitory effect. These findings reveal another antitumor mechanism of statin and identify a potential therapeutic target to treat GBM.
Section snippets
Cell Culture
U87 and U251 human glioma cell lines were purchased from the iCell (Shanghai, China). U87 and U251 cells were maintained in dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 50 μg/mL streptomycin at 37°C in a humidified atmosphere of 5% CO2.
Cell Viability Analysis by CCK8 Assay
The viability of U87 and U251 cells in different conditions was determined by measuring cellular metabolism using 96-well plates. Briefly, 1 × 104 U87 and U251 cells in 200 μL of 10% FBS medium
Simvastatin Suppressed GBM Cell Viability
Simvastatin (Figure 1A) is one of the most widely used statin drugs in clinical treatment. First, we explore the effects of simvastatin on U87 and U251 cells. As shown in Figure 2A, we examined cell viability through CCK8 assay in response to treatment with different concentrations of simvastatin (0.5 μM, 1 μM, 2 μM, 4 μM, and 8 μM) at different time points (24 hours, 48 hours, and 72 hours). Our results showed that from 1 μM concentration of simvastatin, a significant dose-time inhibition
Discussion
Statin drugs have been widely used to treat hypercholesterolemia in the past 2 decades and have made a significant contribution to decreased cardiovascular morbidity and mortality.21 Beyond their cardioprotective effects, however, statins have been reported to have possible benefits regarding immunomodulation in organ transplantation and autoimmune diseases, induction of bone marrow stimulation, and suppression of cancer progression.22,23 A number of studies have prompted clinical trials
CRediT authorship contribution statement
Shulong Yang: Conceptualization, Methodology, Writing – original draft. Chuncheng Xie: Conceptualization, Data curation, Supervision. Tieyun Guo: Visualization, Investigation. Huiying Li: Formal analysis, Visulization. Nannan Li: Data curation, Software, Validation. Song Zhou: Formal analysis, Visualization. Xiuyun Wang: Writing – review & editing.
References (40)
- et al.
The inflammation hypothesis and its potential relevance to statin therapy
Am J Cardiol
(2007) - et al.
Statins in tumor suppression
Cancer Lett
(2008) - et al.
Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells
Biochem biophysical Res Commun
(1994) - et al.
GSDME mediates caspase-3-dependent pyroptosis in gastric cancer
Biochem biophysical Res Commun
(2018) - et al.
Statin use and kidney cancer survival outcomes: a systematic review and meta-analysis
Cancer Treat Rev
(2017) - et al.
Statins and breast cancer prognosis: evidence and opportunities
Lancet Oncol
(2014) - et al.
Statin use and mortality in cancer patients: systematic review and meta-analysis of observational studies
Cancer Treat Rev
(2015) - et al.
Immunotherapy for malignant glioma: current Status and future Directions
Trends Pharmacol Sci
(2020) - et al.
microRNAs in cancer management
Lancet Oncol
(2012) - et al.
Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?
Circulation
(2004)
Current state and future perspective of drug repurposing in malignant glioma
Semin Cancer Biol
Statins are potential anticancerous agents (review)
Oncol Rep
Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells
Cell Death Dis
Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells
Sci Rep
Mevalonate Cascade inhibition by simvastatin induces the Intrinsic apoptosis pathway via Depletion of isoprenoids in tumor cells
Scientific Rep
Simvastatin suppresses proliferation and migration in non-small cell lung cancer via pyroptosis
Int J Biol Sci
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
J Hematol Oncol
NLRP3 inflammasome activation mediates radiation-induced pyroptosis in bone marrow-derived macrophages
Cell Death Dis
miR-186-5p promotes apoptosis by targeting IGF-1 in SH-SY5Y OGD/R model
Int J Biol Sci
Metabolic remodeling, inflammasome activation, and pyroptosis in macrophages stimulated by Porphyromonas gingivalis and its Outer membrane Vesicles
Front Cell Infect Microbiol
Cited by (10)
Inhibition of Caspase-1-mediated pyroptosis promotes osteogenic differentiation, offering a therapeutic target for osteoporosis
2023, International ImmunopharmacologyNew Insights on NLRP3 Inflammasome: Mechanisms of Activation, Inhibition, and Epigenetic Regulation
2024, Journal of Neuroimmune PharmacologyResearch Progress in Pyroptosis, Drug Therapy and Immunotherapy in Glioblastoma
2024, Chinese Journal of Modern Applied PharmacyPyroptosis in glioma: Current management and future application
2024, Immunological ReviewsSimvastatin induces pyroptosis via ROS/caspase-1/GSDMD pathway in colon cancer
2023, Cell Communication and Signaling
Conflict of interest statement: This work was supported by Heilongjiang Education Department Project (12541469).
Shulong Yang and Chuncheng Xie contribute equally to this work.